In pharmaceutical manufacturing routes that convert 1-bromo-3-chloropropane (CAS 109-70-6) into oral tablet APIs, the reagent is used as a difunctional C3 alkylating intermediate rather than as a component of the final tablet blend. The physical properties that govern charging and reactor design are the liquid boiling range of 143–145 °C at 101.3 kPa, the molecular weight of 157.44 g/mol, and the density of approximately 1.59 g/mL at 20 °C. The terminal bromide undergoes S_N2 displacement more readily than the terminal chloride, so sequential substitution can be directed at the bromomethyl site with a secondary amine in acetonitrile at 60–80 °C and anhydrous potassium carbonate. The resulting N-(3-chloropropyl) intermediate is isolated as the free base or hydrochloride salt and recrystallized from isopropanol or methyl ethyl ketone to a melting range suitable for direct compression after milling. The tableting blend is composed of the derived API, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate; 1-bromo-3-chloropropane itself is not present in the compressed core except as a trace process impurity. Because the unreacted halide is assigned to a mutagenic-impurity control strategy under ICH M7(R2), the default acceptable intake of 1.5 µg/day is converted to a residue limit based on the maximum daily dose. For a 100 mg tablet product, this corresponds to 15 ppm in the drug substance. A high-risk intermediate transfer through 316L stainless-steel charging lines, a glass-lined reactor, and PTFE gaskets is used because the reagent can swell elastomeric seals and extract plasticizers into the batch. Reaction progress is monitored by GC-FID on a 30 m × 0.25 mm × 0.25 µm 5% phenylmethylsiloxane column with split injection at 20:1 and detector temperature at 250 °C. Pharm-grade raw material release should include assay by GC not less than 99.0%, individual unknown impurities not more than 0.10%, total impurities not more than 0.50%, and water content not more than 0.10% by Karl Fischer titration. Moisture ingress in the package is the main cause of solvolysis to 3-chloro-1-propanol, and the hydrolysis byproduct can disturb downstream stoichiometry if the reagent is dispensed without prior water verification.

What Limits Alkylator Stoichiometry in Capsule-Directed O-Alkylation of Phenolic Prodrug Intermediates?

For phenolic prodrug intermediates that are later filled into hard gelatin or HPMC capsules, 1-bromo-3-chloropropane is added to a DMF solution of the phenoxide generated from anhydrous potassium carbonate. The reaction is maintained at 55–65 °C for 8–12 hours because lower temperatures leave unreacted reagent, while higher temperatures accelerate 3-chloropropyl ether hydrolysis to the 3-hydroxypropyl ether and reduce bromide-to-chloride selectivity. The molar ratio of alkylator to phenol is fixed at 1.05:1 to 1.10:1; excess reagent is avoided because it can produce diether-bridged propane dimers that are difficult to purge by recrystallization. The reaction is quenched with aqueous ammonium chloride after GC conversion reaches ≥98.0%. The isolated 3-chloropropyl ether is stable under neutral or mildly basic conditions, but prolonged exposure to hot carbonate increases the proportion of 3-hydroxypropyl impurity and can lower the assay to below 95.0% before capsule filling. Capsule-directed granulation of the protected intermediate uses a non-aqueous binder solution based on isopropanol and dichloromethane instead of a water-based starch paste. The reason for avoiding water during wet massing is that the 3-chloropropyl ether undergoes solvolysis and releases ionic chloride, which can reduce hard gelatin shell robustness on stability and trigger cross-linking of gelatin through aldehyde formation. The wet granulate is dried in a vacuum tray dryer at 40–45 °C under ≤50 mbar until Karl Fischer moisture is not more than 0.5%. After drying, the granulate is milled through a 0.8 mm screen and blended with lactose monohydrate and sodium starch glycolate; the bulk density is recorded in the range 0.45–0.60 g/mL to support size 1 capsule filling. The residual 1-bromo-3-chloropropane in the protected intermediate is determined by GC-MS in selected ion monitoring mode at m/z 157 and 159; the analytical limit of quantitation must be sufficiently below the mutagenic-impurity limit derived from ICH M7(R2). For a 500 mg capsule product, the default limit is 3 ppm in the drug substance when the 1.5 µg/day acceptable intake is divided by the daily dose. If a compound-specific acceptable intake is developed under ICH M7(R2) from bacterial mutagenicity data, the limit may be raised or lowered accordingly. Published data for this specific configuration is limited to non-commercial scale batch records and excipient compatibility studies, so process qualification requires spiking and purge confirmation rather than reliance on literature precedents.

Injectable-grade quaternary ammonium API intermediates can be prepared from 1-bromo-3-chloropropane and N,N-dimethyl-substituted tertiary amines in acetone or nitromethane at 20–30 °C. The reaction is exothermic and is controlled by stepwise addition of the liquid alkylating agent at a rate not exceeding 0.5 mL/min per 1 L batch volume; uncontrolled addition produces temperature excursions that increase the proportion of the eliminated alkene byproduct 3-chloropropene. The resulting 3-chloropropyl quaternary ammonium salt is water-soluble and can be converted to a parenteral API after chloride-to-bromide exchange or after displacement of the terminal chloride with a carboxylate nucleophile. Residual acetone from the quaternization step is controlled under ICH Q3C(R7) at 5000 ppm for parenteral drug substances, while acetonitrile from an earlier N-alkylation step carries a limit of 410 ppm and N,N-dimethylformamide a limit of 880 ppm when the daily dose is 10 g/day. In injectable formulations, the residual 1-bromo-3-chloropropane must be reduced below the ICH M7(R2) acceptable intake because the parenteral route has complete systemic availability and no first-pass clearance to reduce exposure. The analytical method for residue quantification uses reverse-phase LC-MS/MS after dilution in cold mobile phase at 2–8 °C; sample preparation at ambient temperature can overestimate active impurity content through thermal solvolysis. The reporting threshold for 1-bromo-3-chloropropane in a parenteral drug substance is set at 1 ppm, and the quantitation limit must be at least 3 times below the calculated specification limit. Terminal heat sterilization at 121 °C for 15 minutes is not relied upon to destroy residual alkylating impurities, because autoclaving can degrade heat-labile linkers without eliminating the starting material. Sterile filtration through 0.22 µm polyvinylidene difluoride membranes removes particulates but does not reduce dissolved high-volatility impurities; the control must therefore be achieved in upstream reactor and isolation steps through closed charging, nitrogen blanketing, and repeated charcoal or scavenger treatment if necessary.

When the 3-Chloropropyl Arm Is Retained Through Final Granulation and Compression

When the 3-chloropropyl arm is retained through the final granulation and compression stages of an oral solid dosage form, the residual alkylator burden is assessed as a combined mutagenic and solvent impurity rather than as a simple unreacted starting-material value. High-shear granulators with a bowl capacity of 600 L and impeller tip speeds of 5–10 m/s can disperse a hydrochloride API derived from 1-bromo-3-chloropropane into a lactose monohydrate and microcrystalline cellulose matrix. The granulation fluid is a 10% w/w aqueous povidone solution, which introduces sufficient water to hydrolyze any residual terminal chloride unless the API has been dried to 0.1% moisture and the granulation is completed within 20 minutes. The wet mass is discharged through a 4 mm screen and dried in a fluid-bed dryer at 60 °C inlet air temperature until loss on drying is below 2.0%. The dried granulate is blended with sodium starch glycolate and magnesium stearate for 3 minutes; over-lubrication is avoided because hydrophobic magnesium stearate can retard disintegration of the compressed tablet. Final tablet hardness is set at 80–120 N for a 300 mg tablet, with disintegration below 15 minutes in 0.1 N hydrochloric acid. Dissolution is measured with USP apparatus II at 50 rpm in 900 mL of pH 1.2 medium; the API derivative must release at least 80% within 30 minutes for an immediate-release profile. Because trace 1-bromo-3-chloropropane may adsorb to the granule surface, an alkaline hydrolysis pre-treatment before headspace GC is used to liberate the compound from the matrix; method recovery must be demonstrated at 0.5 ppm, 1.0 ppm, and 2.0 ppm spiked levels with relative standard deviation below 15%. The batch is rejected if the calculated residual impurity exceeds the ICH M7(R2) default intake, independent of dissolution performance.

Does Reduced-Chloride Solvolysis Extend Reagent Shelf Life in Oral Granule Campaigns?

In oral granule campaigns that use 1-bromo-3-chloropropane as a controlled starting material, water ingress is the main factor that reduces batch-to-batch selectivity. The reagent is stored in amber glass or fluoropolymer-lined containers under nitrogen, and a package-closure integrity test verifies no loss of headspace pressure over 24 hours. Karl Fischer titration is executed at receiving and before dispensing; a limit of 0.10% water is specified because higher moisture levels convert the bromide to 3-chloro-1-propanol and generate hydrogen bromide that corrodes stainless-steel charging lines. Operators dispense the reagent through closed-coupled transfer sets into a reactor already charged with anhydrous potassium carbonate and the amine or phenol substrate; this sequence prevents localized over-concentration of the alkylating agent and reduces formation of the symmetrical 1,3-disubstituted propane impurity. The reactor jacket is set to 65 °C and held for 12–16 hours, with in-process GC samples collected at 2-hour intervals. The reaction is considered complete when residual 1-bromo-3-chloropropane area-percent falls below 0.25% or plateaus for three consecutive samples. After aqueous workup, the organic layer is washed with 5% w/v sodium chloride solution and dried over anhydrous sodium sulfate; residual water in the isolated intermediate is then measured before the granulation step. An impurity tracking matrix based on ICH Q3C(R7) and ICH M7(R2) is applied at each stage for acetonitrile, N,N-dimethylformamide, and 1-bromo-3-chloropropane. The limit for N,N-dimethylformamide in the final drug substance is 880 ppm for oral products, and the limit for 1-bromo-3-chloropropane is dose-adjusted rather than fixed. The process analytical technology loop can include a Fourier-transform infrared probe to monitor the disappearance of the C-Br stretching band near 600 cm⁻¹; this avoids repeated sampling of the reactive mixture and shortens batch cycle time. The reaction temperature, stirrer speed, and jacket heat-transfer coefficient are trended in a distributed control system, and any excursion above 85 °C triggers an automatic quench sequence because thermal acceleration of 3-chloropropene formation creates a pressure rise in a sealed reactor.

Residual Alkylator Limits Across Parenteral Vial, Lyophilized Cake, and Prefilled Syringe Formats

In parenteral formats, the route from 1-bromo-3-chloropropane-derived intermediates to sterile dosage forms includes an additional solubility and stability screen that is not present in oral solid processing. The free base or hydrochloride intermediate is dissolved in a 0.9% w/v sodium chloride vehicle with pH adjusted to 5.0–7.0 with acetate buffer. The solution is sterile-filtered through a 0.22 µm PVDF membrane and filled aseptically into Type I borosilicate glass vials. For a lyophilized cake, the formulation is frozen at −40 °C and primary-dried at −10 °C under 0.1 mbar; the secondary drying ramp is limited by the melting point of the API intermediate and the glass transition temperature of the mannitol matrix. Residual 1-bromo-3-chloropropane is volatile enough to be partially removed in the lyophilization chamber, but the efficiency of removal depends on the cake surface area, the condenser temperature, and the chamber pressure. A pressure-rise test at the end of primary drying confirms no uncontrolled moisture or solvent in the cake. The batch release specification for the vial requires residual 1-bromo-3-chloropropane not more than the dose-adjusted ICH M7(R2) limit; for a 2 mL vial containing 100 mg API, a default limit of 15 ppm in the drug substance is calculated from the 1.5 µg/day acceptable intake. Prefilled syringes require an elastomeric closure compatibility study because brominated residuals can migrate into the siliconized barrel and accelerate the vaporization of silicone oil. The syringe barrel is configured with a staked needle and a fluoropolymer-coated plunger to reduce sorption of lipophilic API intermediates. Final sterilization by steam at 121 °C for 15 minutes is applied only if the API derivative is thermostable; for heat-labile parenteral APIs, aseptic filtration remains the terminal processing step. The limit for residual water in the finished vial is set at 2.0% for lyophilized product and 5.0% for solution vials to constrain hydrolytic release of ionic chloride from the 3-chloropropyl arm. Published data for this specific formulation configuration is limited; method validation and shipping stability are therefore conducted on three consecutive GMP lots before commercial release.